Home > Dermatology > SPIN 2022 > Where Are We Now in Hidradenitis Suppurativa > IHS4 better suited as an outcome measure in HS trials?

IHS4 better suited as an outcome measure in HS trials?

Presented By
Prof. Thrasyvoulos Tzellos, Nordland Hospital Trust, Norway
Conference
SPIN 2022
Doi
https://doi.org/10.55788/70574b24
The International Hidradenitis Suppurativa Severity Score System (IHS4) includes and accentuates draining tunnels. Compared with the currently most often used Hidradenitis Suppurativa Clinical Response (HiSCR) score, IHS4 shows advantages in illustrating study outcomes. Unlike in psoriasis and atopic dermatitis, the inflammatory element of hidradenitis suppurativa (HS) advances [1]. “We have a disease that progresses from an inflammatory component to a scarring component if the inflammatory part is not treated well and early enough,” Prof. Thrasyvoulos Tzellos (Nordland Hospital Trust, Norway) stated. Up to now, adalimumab is the only approved biological treatment, thus, there is still a high unmet need. Still, there is somewhat unimpressive data on drug survival rates of adalimumab in HS (56.3% at 1 year and 30.5% at 2 years), with ineffectiveness being the main reason for discontinuation...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on